PSMA – Targeted Clinical Molecular Imaging of Atherosclerosis: Correlation with Cardiovascular Risk Factors

Abstract

Aim

The early diagnosis of atherosclerotic changes to prevent ischemic events represents a clinical challenge.

Prostate-specific membrane antigen (PSMA) as an established diagnostic in the field of prostate cancer also appears to detect neovascularization and inflammation in other diseases. We hypothesized that it might be also suited for detection of inflammation in atherosclerosis.

Methods

We analyzed data of 78 prostate cancer patients who received a PSMA ligand PET/CT for re-staging. The cardiovascular risk factors (CVRF) of each patient were documented. Target-to-background-ratios (TBR) were calculated from the individual uptake values for three different sections of thoracic aorta [ascending (AA) and descending aorta (AD), aortic arch (AoAC)]. Statistical analyses included a linear regression analysis with the PSMA ligand uptake values of the different arterial segments versus different CVRF as independent variables.

Results

The meanTBRmax was measured highest in the AoAC (1.66 ± 0.33) compared to both other vessel sections (AA: 1.46 ± 0.21, p=0.001; AD: 1.59 ± 0.41, p=0.371). There was a correlation between the PSMA ligand uptake in all measured segments of the aorta and BMI, but only a significant correlation in the ascending aorta (r=0.347, p=0.001). This was confirmed in a subgroup analysis, which showed significantly higher uptake values in preadiposity (BMI >25) and obesity (BMI >30) patients in the ascending aorta (p=0.048).

Conclusion

PSMA ligand uptake in the ascending aorta was linked to BMI. PET detection of vascular PSMA ligand uptake may be indicative of vessel wall inflammation to some extent. However, PSMA ligands appear to be less suitable than other tracers for this purpose, given their absent correlation with most established CVRFs.

Keywords

PET - PSMA - Glutamate carboxypeptidase II - Atherosclerosis - Cardiovascular risk factors

Publikationsverlauf

Eingereicht: 28. März 2024

Angenommen nach Revision: 06. August 2024

Artikel online veröffentlicht:
05. Dezember 2024

• References

• 1 Townsend N, Kazakiewicz D, Wright FL. et al. Epidemiology of cardiovascular disease in Europe. Nat Rev Cardiol 2022; 19 (02) 133-143
• 2 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosism. Circulation 2002; 105: 1135-1143
• 3 Silvestre-Roig C, De Winther MP, Weber C. et al. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 2014; 114: 214-226
• 4 Zhu Y, Xian X, Wang Z. et al. Research progress on the relationship between atherosclerosis and inflammation. Biomolecules 2018; 23: 80
• 5 Geovanini GR, Libby P. Atherosclerosis and inflammation: Overview and updates. Clin Sci (Lond) 2018; 132: 1243-1252
• 6 Pedro-Botet J, Climent E, Benaiges D. Atherosclerosis and inflammation. New therapeutic approaches. Med Clin (Barc) 2020; 155: 256-262
• 7 Xu J, Lu XShi GP. Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci 2015; 16: 11574-11608
• 8 Bourantas CV, Garcia-Garcia HM, Farooq V. et al. Clinical and angiographic characteristics of patients likely to have vulnerable plaques: analysis from the PROSPECT study. JACC Cardiovasc Imaging 2013; 6: 1263-1272
• 9 Chen W, Bural GG, Torigian DA. et al. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2009; 36: 144-151
• 10 Sun Z. Atherosclerosis and atheroma plaque rupture: imaging modalities in the visualization of vasa vasorum and atherosclerotic plaques. Scientific World Journal 2014; 2014: 312764
• 11 Herrmann J, Lerman LO, Rodriguez-Porcel M. et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 2001; 51: 762-766
• 12 Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014; 11: 443-457
• 13 Bucerius J, Hyafil F, Verberne HJ. et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging 2016; 43: 780-792
• 14 Maurer T, Eiber M, Schwaiger M. et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016; 13: 226-235
• 15 Regula N, Kostaras V, Johansson S. et al. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse. Sci Rep 2020; 10 (01) 4993
• 16 Young S, Liu W, Zukotynski K. et al. Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician's guide. Expert Rev Anticancer Ther 2021; 21 (06) 641-655
• 17 Chang SS, Reuter VE, Heston WD. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192-3198
• 18 Endepols H, Mottaghy FM, Simsekyilmaz S. et al. In vivo molecular imaging of glutamate carboxypeptidase II expression in re-endothelialisation after percutaneous balloon denudation in a rat model. Sci Rep 2018; 8: 7411
• 19 Gao J, Meng L, Xu Q. et al. Ga-PSMA-11 PET/CT parameter correlates with pathological VEGFR-2/PDGFR-β expression in renal cell carcinoma patients. Mol Imaging Biol 2022; 24: 759-768
• 20 Gündoğan C, Ergül N, Çakir MS. et al. 68Ga-PSMA PET/CT versus 18F-FDG PET/CT for imaging of hepatocellular carcinoma. Mol Imaging Radionucl Ther 2021; 30: 79-85
• 21 Lisney AR, Leitsmann C, Strauß A. et al. The role of PSMA PET/CT in the primary diagnosis and follow-up of prostate cancer-A practical clinical review. Cancers (Basel) 2022; 26: 3638
• 22 De Galiza Barbosa F, Queiroz MA, Nunes RF. et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 2020; 20: 23
• 23 Shetty D, Patel D, Le K. et al. Pitfalls in Gallium-68 PSMA PET/CT interpretation – A pictorial review. Tomography 2018; 4: 182-193
• 24 Derlin T, Thiele J, Weiberg D. et al. Evaluation of 68Ga-Glutamate carboxypeptidase II ligand positron emission tomography for clinical molecular imaging of atherosclerotic plaque neovascularization. Arterioscler Thromb Vasc Biol 2016; 36: 2213-2219
• 25 Ozcan PP, Serdengecti M, Koc ZP. et al. Cancers and Benign processes on 68 Ga PSMA PET-CT imaging other than prostate cancer. World J Nucl Med 2022; 21: 106-111
• 26 Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. 2022 Jun 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022
• 27 Bucerius J, Mani V, Wong S. et al. Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging 2014; 41: 934-945
• 28 Bucerius J, Vijgen GHEJ, Brans B. et al. Impact of bariatric surgery on carotid artery inflammation and the metabolic activity in different adipose tissues. Medicine (Baltimore) 2015; 94: e725
• 29 Fujimoto S, Yasaka M, Otsubo R. et al. Aortic arch atherosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004; 35: 1426-1429
• 30 Di Tullio MR, Russo C, Jin Z. et al. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009; 119: 2376-2382
• 31 Truijman MTB, Kwee RM, van Hoof RHM. et al. Combined 18F-FDG PET-CT and DCE-MRI to assess inflammation and microvascularization in atherosclerotic plaques. Stroke 2013; 44: 3568-3570
• 32 Bural GG, Torigian DA, Chamroonrat W. et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging 2008; 35: 562-569
• 33 Høilund-Carlsen PF, Piri R, Constantinescu C. et al. Atherosclerosis Imaging with 18F-Sodium Fluoride PET. Diagnostics (Basel) 2020; 10 (10) 852
• 34 Jensen JK, Madsen JS, Jensen MEK. et al. [64Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans. J Nucl Cardiol 2022; 30: 986-1000
• 35 Sadeghi MM. (18)F-FDG PET and vascular inflammation: time to refine the paradigm?. J Nucl Cardiol 2015; 22 (02) 319-324
• 36 Tavakoli S, Zamora D, Ullevig S. et al. Bioenergetic profiles diverge during macrophage polarization: implications for the interpretation of 18F-FDG PET imaging of atherosclerosis. J Nucl Med 2013; 54 (09) 1661-1667
• 37 Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009; 6: 399-409
• 38 Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol 2015; 31: 177-183